Renal Function Decline With Small Interfering RNA Silencing Aminolevulinic Acid Synthase 1 (ALAS1)

INTRODUCTION: Givosiran is an RNA interference therapeutic designed to block the synthesis of the aminolevulinic acid (ALA) synthase 1 (ALAS1) enzyme in patients with acute intermittent porphyria (AIP). Givosiran may have adverse effects on the kidney. METHODS: We performed a descriptive case series...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Kidney Int Rep
Autors principals: Lazareth, Hélène, Poli, Antoine, Bignon, Yohan, Mirmiran, Arienne, Rabant, Marion, Cohen, Raphaël, Schmitt, Caroline, Puy, Hervé, Karras, Alexandre, Gouya, Laurent, Pallet, Nicolas
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2021
Matèries:
Clinical Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8258458/
https://ncbi.nlm.nih.gov/pubmed/34307985
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ekir.2021.04.004
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars